Program
Drugs, Investigational
Also written as “Investigational drug”, “Investigational new drug, company code: BGG492” and “TimoD implant”.
Its studies are mostly in Keratosis, Actinic · Glaucoma · Burns · Glaucoma, Open-Angle · Nervous System Diseases, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| EyeD Pharma | 21 open or running | phase 2since Jun 17, 2025 | Mar 13, 2024 | Jan 2027phase 2 · NCT07036510 |
| Novartis | 20 open or running | phase 2since Apr 23, 2009 | Apr 23, 2009 | none ahead |
| Pfizer | 20 open or running | phase 2since May 2, 2002 | May 2, 2002 | none ahead |
| Bristol-Myers Squibb | 10 open or running | phase 2since Jun 26, 2002 | Jun 26, 2002 | none ahead |
| Merck | 10 open or running | phase 3since Aug 25, 2000 | Aug 25, 2000 | none ahead |
| Skingenix | 11 open or running | phase 2since Feb 14, 2011 | Feb 14, 2011 | Dec 31, 2026phase 2 · NCT01297400 |
| Sun Pharmaceutical Industries | 11 open or running | phase 1since Jul 22, 2026 | Jul 22, 2026 | Dec 2026phase 1 · NCT07729579 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 25, 2000First study: phase 3 study in Alzheimer DiseaseNew to MerckMerck · NCT00006187 · United States
- May 2, 2002Pfizer’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to PfizerPfizer · NCT00034957 · United States
- May 8, 2002Phase 1 study in Multiple MyelomaPfizer · NCT00036140 · United States
- Jun 26, 2002Bristol-Myers Squibb’s first study: phase 2 study in Colorectal NeoplasmsNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT00040391 · United States
- Apr 23, 2009Novartis’s first study: phase 2 study in SeizuresNew to NovartisNovartis · NCT00887861 · 37 enrolled · Germany
- Jun 15, 2010Phase 2 study in Nervous System DiseasesNovartis · NCT01147003 · 93 enrolled · United States, Bulgaria, Germany and more
- Feb 14, 2011Skingenix’s first study: phase 2 study in BurnsNew to SkingenixSkingenix · NCT01297400 · 60 planned · United States, Mexico
- Mar 13, 2024EyeD Pharma’s first study: phase 1 study in Glaucoma, Open-AngleNew to EyeD PharmaEyeD Pharma · NCT06321562 · 1 enrolled · Germany
- Jun 17, 2025Phase 2 study in GlaucomaEyeD Pharma · NCT07036510 · 42 planned · Panama
- Jul 22, 2026Sun Pharmaceutical Industries’ first study: phase 1 study in Keratosis, ActinicNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT07729579 · 48 planned · United States
Ahead
- Dec 2026Primary completion: phase 1 study in Keratosis, ActinicSun Pharmaceutical Industries · NCT07729579
- Dec 31, 2026Primary completion: phase 2 study in BurnsSkingenix · NCT01297400
- Jan 2027Primary completion: phase 2 study in GlaucomaEyeD Pharma · NCT07036510
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07729579Keratosis, Actinic · United States | 1 | Recruiting | Sun Pharmaceutical Industries | Dec 2026 | 48 |
| NCT07036510Glaucoma · Panama | 2 | Recruiting | EyeD Pharma | Jan 2027 | 42 |
| NCT06321562Glaucoma, Open-Angle · Germany | 1 | Terminated | EyeD Pharma | Jun 26, 2025 | 1 |
| NCT01297400Burns · United States, Mexico | 2 | Recruiting | Skingenix | Dec 31, 2026 | 60 |
| NCT01147003Nervous System Diseases · United States, Bulgaria, Germany and more | 2 | Completed | Novartis | Sep 2011 | 93 |
| NCT00887861Seizures · Germany | 2 | Completed | Novartis | Aug 2010 | 37 |
| NCT00040391Colorectal Neoplasms · United States | 2 | Terminated | Bristol-Myers Squibb | ||
| NCT00036140Multiple Myeloma · United States | 1 | Completed | Pfizer | ||
| NCT00034957Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Pfizer | Oct 2002 | |
| NCT00006187Alzheimer Disease · United States | 3 | Terminated | Merck | Jun 2005 |
How it is read
Names in the registry
- “Investigational drug”, 5 entries
- “Investigational new drug, company code: BGG492”, 3 entries
- “TimoD implant”, 2 entries
- “Investigational Drug, MW-III”, 1 entry
Conditions, from the studies’ own filings
- Keratosis, Actinic, 1 study
- Glaucoma, 1 study
- Burns, 1 study
- Glaucoma, Open-Angle, 1 study
- Nervous System Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.